-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1839 Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Diseases, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Marie Sebert, MD, PhD1*, Sylvie Chevret2*, Sophie Dimicoli-Salazar, MD3*, Thomas Cluzeau, MD, PhD4*, Odile Rauzy, MD5*, Aspasia Stamatoulas Bastard, MD6*, Kamel Laribi7*, Gaelle Fossard8*, Sylvain Thépot, MD9,10*, Silke Gloaguen, MSc11*, Kristell Desseaux12*, Norbert Vey, MD13, Pierre Peterlin14*, Anne-Laure Taksin15*, Caroline Lejeune16*, Sophie Park, MD, PhD17, Anne Banos, MD18*, Aristoteles Giagounidis, MD19, Emmanuel Gyan, MD, PhD20, Mario Ojeda-Uribe, MD21*, Stefanie Groepper, MD22*, Fatiha Chermat23*, Emmanuelle Clappier, Pharm.D., Ph.D.24*, Uwe Platzbecker, MD25, Pierre Fenaux, MD26 and Lionel Ades, MD, PhD27

1Hematology department, Saint-Louis Hospital, Paris, France
2Biostatistics and Medical Information Department, Saint Louis Hospital, Assistance Publique — Hôpitaux de Paris (AP-HP), Paris, France
3Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
4Centre Hospitalier Universitaire de Nice, Nice, France
5Department for Internal Medicine, Toulouse University Hospital, Toulouse, France
6Centre Henri Becquerel, Rouen, FRA
7Hématologie Clinique, CH Le Mans, Le Mans, France
8Department of Hematology, Lyon Sud Hospital, Pierre Benite, FRA
9Service des Maladies du Sang, CHU Angers, Angers, France
10Centre Hospitalier Universitaire d'Angers, Angers, France
11GWT-TUD Gmbh, Dresden, Sachsen, DEU
12Department of Biostatistics and Medical Informatics,, Hôpital Saint Louis, GHU AP-HP Nord Université Paris Cité, Paris, FRA
13Department of Hematology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille, France
14Hematology Department, Hôtel-Dieu University Hospital, NANTES CEDEX 1, France
15CHu de Versailles, Versailles, France
16Hematology department, ICLN, CHU Saint-Etienne, Saint etienne, France
17Hematology Department, CHU Grenoble, Grenoble Cedex 9, France
18Centre Hospitalier De Bayonne, Bayonne, FRA
19Clinic for Hematology, Oncology and Palliative Care Marien Hospital Düsseldorf, Dusseldorf, Germany
20Service D'Hematologie Et Therapie Cellulaire, Tours Cedex, France
21Clinical Hematology Department, Mulhouse Hospital, Mulhouse, France, Mulhouse, FRA
22Marien Hospital, University of Düsseldorf, Düsseldorf, Germany
23Groupe Francophone des Myelodysplasies, Hôpital St Louis/université de Paris Cité, Paris, FRA
24Saint Louis Hospital, Paris, France
25Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
26Hopital Saint Louis, Groupe Francophone des Myelodysplasies, Paris, France, PARIS, FRA
27Hopital Saint Louis, Paris, France

Introduction: ENA, a selective inhibitor of IDH2 mutated protein, is FDA approved for the treatment of patients with relapsed/refractory IDH2 mutated (IDH2m) AML. There are limited data on its efficacy as a single agent in patients with IDH2m MDS. Here we report the preliminary results of a Phase 2 trial evaluating the safety and efficacy of ENA in three different cohorts of MDS: Higher risk (HR-) MDS having failed HMA (cohort A), untreated HR- MDS without life threatening cytopenias (cohort B) and lower risk MDS having failed ESA (cohort C). (ClinicalTrials.gov NCT03744390).

Methods: Subjects were enrolled in cohort A, B, or C received continuous 28-day cycles of ENA - 100 mg PO QD. In cohort B, in the absence response after 3 cycles, Azacitidine (AZA, 75 mg/m2/d x 7 days, SC) was added to ENA. A Fleming single stage phase 2 trial, used the best overall hematological response (OR, including CR, PR, stable disease or marrow CR with HI according to IWG 2006) as the primary endpoint for cohort A and B, aiming to demonstrate a OR>20%; and a safety endpoint in cohort C. All patients who achieved OR could continue treatment until loss of response. Secondary endpoints included safety, duration of response, EFS, overall survival (OS) and translational studies evaluating the role of biomarkers on response.

Results: Between February 2019 and November 2022, 95 patients were screened, 69 were included (28, 30 and 11 in cohort A, B and C, respectively). Median age at screening was 76 years (IQR 71-81) and 36% were female. According to WHO 2016, 4 (6%) had MDS-SLD (including 3 MDS-RS-MLD), 7 (10%) MDS-MLD (including 5 MDS-RS-MLD), 13 (19%) MDS-EB1, 26 (38%) MDS-EB2, one (1%) MDS-U, 3 (4%) CMML and 15 (22%) low-blast AML. IPSS-R was low, intermediate, high and very high in 8 (12%), 16 (23%), 34 (49%) and 11 (16%) respectively. IDH2m variants were p.R140L/Q/W (85%) and p.R172K/W (15%). The median VAF of IDH2m in bone marrow at screening was 36.6% (IQR 22.2-42.2).

In cohort A, best OR after 3 or 6 cycles was achieved in 12/28 (42.9%) patients (95%CI, 24.5-62.8) (p=0.007), including 5 (42%) CR, and 7 (58%) HI, with a median DOR of 6.9 months. All responders achieved a response at 3 cycles. At data cut-off (Jan. 2024), 21 patients had died (mainly from disease) and 2 are still alive on therapy (after 28 and 41 cycles). With a median FU of 13.7 months, median OS was 14.9 months, and the 12-month OS rate was 57.1% (95%CI, 41.5-78.8).

In cohort B, primary endpoint was achieved in 13/30 (43.3%) patients (95%CI 25.5-62.6) (p=0.004), including 5 (38%) CR, 2 (15%) PR and 6 (46%) HI, with a median DOR of 12.2 months. AZA was added to ENA in 4 patients after 3 cycles leading to one additional response. Two patients were bridged to transplant. At data cut-off, 17 patients had died, and 2 are still alive on therapy (after 33 and 54 cycles). With a median follow-up of 19.8 months, median OS was 25.5 months and the 12-month OS rate was 85.8% (95%CI, 73.9-99.7).

With 72 grade 3 or more (3+) adverse events (AE), mainly related to cytopenia and occurring in 45/58 (78%) patients of HR-MDS cohorts (A and B), ENA was well tolerated. None of the 87 severe AE (SAE) were related to ENA in these two cohorts. Differentiation syndromes were manageable and reported in 5/58 (8.6%) patients.

In cohort C, one patient without IDH2m discontinued treatment after one cycle. Five patients had grade 3+ AE, related to ENA in two patients (thrombocytopenia and increasing bilirubin level), all resolved after drug temporary interruption. None of the four SAE reported in four patients were related to ENA and no differentiation syndrome was reported in this LR-MDS cohort. In intention to treat analysis, 6/11 (55%) patients achieved CR with transfusion independency, with a median time to response of 3 cycles. At data cut-off, none of the responders had lost response, two were bridged to transplant after 4 and 7 cycles and only one patient died (not related to disease or ENA). The median FU was 29.9 months and the median OS was not reached.

Conclusion: In IDH2m HR-MDS patients, we reported an overall response of 43.1% (95%CI, 30.2-56.8) (p<0.001) with ENA monotherapy, leading to an OS of 14.9 and 25.5 months in R/R and first-line treated patients respectively. In both HR-MDS cohorts, ENA was well tolerated in this frail population. Results from 11 IDH2m LR-MDS patients included in this study show that ENA has no limiting toxicity and can provide durable response in more than half of the patients.

Disclosures: Sebert: Gilead: Honoraria; Jazz Pharmaceutical: Honoraria; BMS: Honoraria; Servier: Honoraria, Research Funding; Abbvie: Honoraria. Laribi: Jansen: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria; BMS: Honoraria; Amgen: Honoraria; Takeda: Honoraria; BeiGene: Honoraria; AstraZeneca: Honoraria; Abbvie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Thépot: BMS, Gilead, Abbvie: Honoraria. Park: Janssen: Research Funding; BMS/Celgene: Honoraria, Other: Travel Support & Meetings, Research Funding; Pfizer: Honoraria, Other: Travel Support & Meetings, Research Funding; Novartis: Honoraria, Research Funding. Giagounidis: Amgen: Consultancy; BMS: Consultancy. Gyan: BMS, Sandoz: Research Funding; AstraZeneca, Abbvie, Janssen, Roche, BMS, Sanofi, Kephren Publishing, Recordati, Novartis, Incyte, Axonal, Servier, Gilead Kite: Honoraria. Groepper: BMS: Honoraria; Sobi: Honoraria; Pfizer: Honoraria; GSK: Honoraria. Platzbecker: MDS Foundation: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding. Fenaux: Janssen: Research Funding; Servier: Research Funding; Astex: Research Funding; Novartis: Research Funding; Agios: Research Funding; AbbVie: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding. Ades: Abbvie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; BMS: Honoraria, Research Funding.

*signifies non-member of ASH